PATENT CLAIM ANALYSIS

Application Number: 16137709
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "489000"]

Abstract:
Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.

Claim (Index 22):
The NDC of  claim 5 , wherein the imaging agent comprises a fluorescent compound.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 97.0
- Lexical Diversity: 1.40816
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14722307', '15124360', '10659501', '14914787', '14406163']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6825888475902672
- 35 USC 102 Novelty (BERT): 0.6350997322885187
- Combined Prediction Score: 0.6778399360600923
- Mean Citation Score: 317.75678800000014
- Max Citation Score: 696.1783
- Similarity Product: 505.9919494587958

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test